BiomX Report the Completion of Patient Dosing in Part 2 of the P-Ib/IIa Study for BX004 to Treat Chronic Pulmonary Infections in Patients with Cystic Fibrosis
Shots:
- The patient dosing has been completed in Part 2 of the P-Ib/IIa trial evaluating BX004 in CF patients with chronic pulmonary infections caused by Pseudomonas aeruginosa (or P. aeruginosa). The Part 2 results of the study are expected in Nov 2023
- The part 1 data of the P-Ib/IIa study was accepted for oral presentation at IDWeek 2023 along with ECFS conference and the European Respiratory Society (ERS) Congress
- BX004 was developed using a proprietary BOLT platform & received the FTD in Aug 2023 for the treatment of chronic respiratory infections caused by Pseudomonas aeruginosa (PsA) bacterial strains in patients with CF
Ref: Globenewswire | Image: BiomX
Related News:- Boehringer Ingelheim Collaborates with BiomX to Discover Microbiome-Based Biomarkers for Inflammatory Bowel Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
